Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB CEO to chair IMI board for second term

UCB CEO to chair IMI board for second term

7th April 2014

UCB has announced that its chief executive officer Roch Doliveux has once again been appointed as chair of the governing board of the Innovative Medicines Initiative (IMI).

Mr Doliveux originally joined the organisation's governing board in May 2010 and acted as its chair from 2012 to 2013. He has been selected for a second term in recognition of his leadership skills and strong focus on the needs of patients.

IMI is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations. UCB has been a member of the partnership since its inception in 2006.

It currently supports 46 projects addressing some of the biggest challenges in medicines research, including enabling better access to treatment worldwide, as well as various education and training projects.

Mr Doliveux said: "IMI is the biggest public-private partnership of its kind and a role model for open innovation and knowledge sharing between the industry and academia."

UCB's CEO is to step down from his position in charge of the company at the end of the year, with Jean-Christophe Tellier having been appointed as his successor.ADNFCR-8000103-ID-801710272-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.